Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Project BioShield” Model Could Apply More Broadly, FDA Commissioner Says

Executive Summary

"Project BioShield" offers a model that policymakers should consider to encourage research in infectious diseases, FDA Commissioner McClellan told the Commonwealth Club in San Francisco June 9

You may also be interested in...



R&D “Pull” Incentives For Vaccines Need $250 Mil. Guarantee – Brookings

Incentive programs to encourage development of vaccines for diseases of the developing world would need to ensure a market of $250 mil.-$500 mil. to be effective, Brookings Institution Senior Fellow Michael Kremer, PhD, said

R&D “Pull” Incentives For Vaccines Need $250 Mil. Guarantee – Brookings

Incentive programs to encourage development of vaccines for diseases of the developing world would need to ensure a market of $250 mil.-$500 mil. to be effective, Brookings Institution Senior Fellow Michael Kremer, PhD, said

Labeling And Liability: FDA Wary Of “Over-Warning,” “Piling On” By Lawyers

Trial lawyers should work with FDA to focus product liability actions on cases where manufacturers appear to be withholding information, Commissioner McClellan suggested during the National Community Pharmacists Association legislative conference May 19 in Washington, D.C

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS041978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel